Literature DB >> 10606278

Complications of advanced prostate cancer.

J A Smith1, M S Soloway, M J Young.   

Abstract

Currently, there is a lot of focus directed toward discovering treatments for patients with hormone refractory prostate cancer (HRPC) that will lead to increased survival. Until such treatments emerge, palliation is important to ensure patients the highest possible quality of life. Most disabling among symptoms associated with disease progression are bone pain, bone fracture, urinary tract obstruction, spinal cord compression, coagulation disorders, anemia, and edema. Diverse treatments, such as radiation therapy, surgery, chemotherapy, and supportive measures, can improve the impact of these problems, although improved symptom control is needed in some areas.

Entities:  

Mesh:

Year:  1999        PMID: 10606278     DOI: 10.1016/s0090-4295(99)00448-3

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  14 in total

1.  The relationship of palliative transurethral resection of the prostate with disease progression in patients with prostate cancer.

Authors:  Tracey L Krupski; George J Stukenborg; Kihyuck Moon; Dan Theodorescu
Journal:  BJU Int       Date:  2010-11       Impact factor: 5.588

2.  The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer.

Authors:  William A See; Chris J Tyrrell
Journal:  J Cancer Res Clin Oncol       Date:  2006-08       Impact factor: 4.553

3.  Disseminated Intravascular Coagulation and Excessive Fibrinolysis (DIC XFL) Syndrome in Prostate Cancer: A Rare Complicated Disorder.

Authors:  Azhar Bin Amir Hamzah; Yew Maw Choo; Mohamed Azmi Hassali; Fahad Saleem; Ashutosh Kumar Verma
Journal:  J Clin Diagn Res       Date:  2017-01-01

4.  Assessment of Real-World Central Nervous System Events in Patients with Advanced Prostate Cancer Using Abiraterone Acetate, Bicalutamide, Enzalutamide, or Chemotherapy.

Authors:  Dominic Pilon; Ajay S Behl; Lorie A Ellis; Marie-Noëlle Robitaille; Patrick Lefebvre; Nancy A Dawson
Journal:  Am Health Drug Benefits       Date:  2017-05

5.  Disseminated intravascular coagulation as the presenting sign of metastatic prostate cancer.

Authors:  Ignacio Duran; Ian F Tannock
Journal:  J Gen Intern Med       Date:  2006-11       Impact factor: 5.128

6.  Anemia in men with advanced prostate cancer: incidence, etiology, and treatment.

Authors:  Jeffrey G Nalesnik; Angela G Mysliwiec; Edith Canby-Hagino
Journal:  Rev Urol       Date:  2004

Review 7.  Early versus delayed hormonal treatment in locally advanced or asymptomatic metastatic prostatic cancer patient dilemma.

Authors:  Domenico Prezioso; Fabrizio Iacono; Giuseppe Romeo; Antonio Ruffo; Nicola Russo; Ester Illiano
Journal:  World J Urol       Date:  2013-08-08       Impact factor: 4.226

8.  Analysis of urological procedures in men who died from prostate cancer using a population-based approach.

Authors:  Kara Babaian; Matthew Truong; Jeremy Cetnar; Deanna S Cross; Fangfang Shi; Mark A Ritter; David F Jarrard
Journal:  BJU Int       Date:  2012-11-06       Impact factor: 5.588

9.  Acute renal failure as the presenting sign of disseminated intravascular coagulation in a patient with metastatic prostate cancer.

Authors:  Ryuji Ohashi; Yusuke Hosokawa; Go Kimura; Yukihiro Kondo; Keiji Tanaka; Shinichi Tsuchiya
Journal:  Int J Nephrol Renovasc Dis       Date:  2013-03-06

10.  Severe bleeding tendency caused by a rare complication of excessive fibrinolysis with disseminated intravascular coagulation in a 51-year-old Japanese man with prostate cancer: a case report.

Authors:  Yoshihiro Wada; Mitsuhiro Uchiba; Yoshiaki Kawano; Nobuyuki Kai; Wataru Takahashi; Jiro Honda; Ken-Ichiro Tanoue; Yoshihiro Maeda; Yoji Murakami; Masatoshi Eto; Takahisa Imamura
Journal:  J Med Case Rep       Date:  2012-11-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.